Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high ‐dose statin

ConclusionsThese studies demonstrated that bococizumab safely and effectively lowered LDL‐C in hypercholesterolemic subjects on high doses of statin.This article is protected by copyright. All rights reserved.

Source: Cardiovascular Therapeutics - October 1, 2017 Category: Cardiology Authors: Sergio Fazio, David G. Robertson, Tenshang Joh, Hong Wan, Tom Riel, Philippe Forgues, Charles M. Baum, Pamela D. Garzone, Barry Gumbiner Tags: Original Research Article Source Type: research